Login to Your Account

Other News To Note

Thursday, November 1, 2012

• Cytovance Biologics Inc., of Oklahoma City, and Fountain BioPharma Inc., of Taiwan, executed a biopharmaceutical development and manufacturing collaboration for FB301, a monoclonal antibody under development by Fountain with a lead indication of allergic disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription